Abbas and Mahalingam (2009) described a rare frame-shift mutation in MSH2, contributing to the expanding mutational spectrum of MTS [5]. Insights from novel sequencing technologies such as spatial transcriptomics could inform resistance mechanisms and recurrence in MTS-related cancers, potentially guiding more effective treatment strategies [17]. This evidence concerns the gene MSH2 and cancer.